Inhibition of sodium-glucose cotransporter 2 prevents sorafenib-induced depression-like behaviors by preserving hippocampal-dependent long-term potentiation. (PubMed, Pharmacol Biochem Behav) - Sep 26, 2026 - "Co-treatment with empagliflozin effectively prevented these neurological and cellular changes. Inhibition of sodium-glucose cotransporter-2 prevents sorafenib-induced depression-like behaviors and suppresses the decline in synaptic transmission and LTP in the hippocampus, thereby contributing to the antidepressant effects of empagliflozin."
Journal • Cardiovascular • CNS Disorders • Depression • Mood Disorders • Psychiatry
|
|
Cheng-Chun Wu; Ming Tatt Lee; Tian-Huei Chu; Tien-Wei Hsu; Wei-Hao Peng; Yu-Cheng Ho; Yu-Ning Teng; Yung-Kuo Lee
|